Ability Pharma
real medicine for real life

Meet Ability Pharma



CONTENTS

Thank you for your interest

AbilityPharma is a biopharmaceutical company focused on the development of new molecules to treat multiple aggressive cancers, which eliminate cancer cells.

Cancer is the second leading cause of death in the world. There is an important need for drugs to effectively and safely stop the progression of this disease. At AbilityPharma we work with the aim of stopping cancer from being a life-threatening disease.

We have spent several years studying a specific drug, called ABTL0812, which has shown to be able to induce the death of cancer cells through autophagy (self-digestion).

ABTL0812 is currently in phase 2 clinical trials to treat endometrial cancer and lung cancer in 80 patients in centers of Spain and France.

Nuestro equipo

AbilityPharma has an experienced senior management team and a team of external advisors with proven success in drug research and development, and in accomplishing license agreements with Big Pharma.

Management team

Carles Domènech, PhD
CEO and co-founder

Carles Domènech is CEO and co-founder of AbilityPharma since its incorporation in 2009. Carles is a biologist graduated from the Autonomous University of Barcelona and holds a Ph.D. in cell biology from the same university. He worked as a postdoctoral investigator at Memorial Sloan-Kettering Cancer Center in New York. After his experience in science research, Carles held positions at Almirall, SA as Head of Business Development and Licensing for 12 years and at Lacer, SA as Director of Business Development and Licensing. Carles also has 4 years experience in biotech venture capital and in business angel associations.

José Alfón, PhD
VP, Research and Development

José Alfón joined AbilityPharma in 2010 as Director of Research and Development. José holds a degree in pharmacy from the Hebrew University of Jerusalem and a PhD in pharmacology from the University of Barcelona. José has more than 20 years of experience in drug development, and worked at J. Uriach i Cia, SA (and later in its spin-off Palau Pharma, SA) where he led discovery and drug development programs.

Gemma Fierro, MSc
VP, Clinical and Regulatory Affairs

Gemma Fierro joined AbilityPharma as Clinical and Regulatory Affairs Director in 2016. Gemma obtained her BS in Pharmacy at the University of Barcelona and her Master in European Regulatory Affairs at the Autonomous University of Barcelona. In 2004, she became Director of Regulatory Affairs for Spain and Portugal at Procter & Gamble, where she later took additional responsibilities, comprising regulatory affairs in all European countries. Later, Gemma joined Bayer Hispania as Head of Regulatory Affairs (2012 – 2014), where she was also involved in clinical trials.

Vanessa Ruz, MSc
VP, Finance and Administration

Vanessa Ruz joined Abilitypharma in 2010. She holds a bachelor's degree and a master's degree in Economics from the Pompeu Fabra University in Barcelona and specialized in business administration. Before joining the company, Vanessa was the Financial Director of Sevibe Cells for 2 years.

Key Team

Marc Cortal, MD
Director, Clinical Research

María Jesús Guerrero
Director, Project Management

Héctor Pérez-Montoyo, PhD
Director, Biological Research

Marc Yeste, PhD
Director, Translational Research

Albert Marofa, MSc
Manager, Business Development and Licensing

Advisors

Dr. Toni Pérez

Chairman of the Clinical Advisory Board - More than 30 years in the pharmaceutical industry in managerial clinical research positions at Esteve, Almirall and Novartis.

Dr. José Miguel Lizcano

Chairman of the Scientific Advisory Board - Professor and Director of the Department of Biochemistry of the Faculty of Medicine at the Autonomous University of Barcelona.

Dr. Pere Gascón

Previous director and senior consultant of the clinical oncology service at Hospital Clínic Barcelona. Former Head of the Oncology Service at the State Medical School of New Jersey for more than 15 years.

Dr. Jordi Rodón

Head of the Early Clinical Drug Development Group at Vall d'Hebron Institut d'Oncologis (VHIO). Associate Professor at MD Anderson Cancer Center, Texas.

Our goal

When we started AbilityPharma, our goal was to make our contribution to the fight against cancer. After a small initial investment to perform proof of concept tests in preclinical models, we decided to start the development of the product. In a few years we have brought the product to international clinical studies aimed at proof of concept in patients.

> “We want to prolong patient lives as much as possible and to improve their quality of life.”

With our product ABTL0812, we want to turn cancer into a chronic and non-lethal disease. In the studies we are doing in patients, we combine our product ABTL0812 with chemotherapy with the aim of obtaining a higher response rate - more efficacy -in patients, but without increasing the toxic effects of chemotherapy. After chemotherapy, the treatment consists in the administration of ABTL0812 as single-agent to decrease and delay the relapse to the disease.

Our drug

The key differentiation of our drug ABTL0812 is its excellent safety and tolerability profile in patients, together with its high potential in several cancer types.

High safety

One way to measure the safety profile of a drug is through the concept "therapeutic margin." This parameter indicates the difference between therapeutic doses and toxic doses: the bigger the therapeutic margin is, the safest the drug is. Comparing with main competing products, which have therapeutic margins between 0.3 and 4.8, ABTL0812's is 8.3, which corroborates the extremely safe profile of our product.

Preclinical Efficacy

In animal cancer models ABTL0812 is effective as single agent with an excellent safety profile in a broad spectrum of cancer types: lung, endometrium and pancreatic cancer, and neuroblastoma. ABTL0812 is also active in cells resistant to other targeted therapies, in tumor stem cells and inhibits the formation of metastasis. Preliminary results show promising immunomodulatory effects as well.

Phase 1: first-in-humans clinical trial

In the first-in-humans phase 1/1b clinical trial in 29 patients with advanced solid tumors, ABTL0812 showed better safety and tolerability compared to other PI3K/Akt/mTOR inhibitors. Efficacy in patients was comparable to the best inhibitors of PI3K/Akt/mTOR in similar clinical trials. It should be noted that 2 patients had more than one-year long disease stabilizations (14 and 18 months).

In addition, ABTL0812 showed high efficacy on biomarkers of the PI3K/Akt/mTOR pathway, with PK/PD correlation. Due to its extremely low toxicity, the recommended dose of phase 2 (RP2D) was determined by PK/PD, without reaching any dose-limiting toxicity.

Phase 2 in endometrial cancer or lung cancer

Currently, AbilityPharma is conducting a phase 1/2a clinical trial in 80 patients with ABTL0812 (at RP2D) as first-line treatment in endometrial cancer and in squamous NSCLC. After the chemotherapy cycles, patients continue to be treated chronically with ABTL0812.

The objective of the trial is to demonstrate that the synergy of ABTL0812 with the chemotherapy observed in preclinical studies is also happening in humans, so we can increase the efficacy of chemotherapy without increasing its toxicity, and thereafter to delay relapses to cancer administering ABTL0812 in monotherapy. The study includes leading centers in Spain and France.



Crowdfunding campaign #notwithoutyou

We want our project to become a real therapeutic option, we want to defeat cancer and to turn it into a non-lethal disease.

Due to the high investment in R&D required for the development of drugs, we have decided to start a crowdfunding campaign to maximize the value of our project during the negotiations of a Series A financing round with international venture capital funds planned for the fourth quarter of 2018.

The objective of the current crowdfunding campaign through **Capital Cell**, is to obtain 1 million euros to complete the phase 1/2 study with the development of additional biomarkers and with the development of a new formulation. We forecast that the exit will be through an IPO in a stock market at the end of 2019 or through a licensing agreement or trade sale of the company to a pharmaceutical multinational in 2020-2021.

Having the opportunity to invest in a company with a drug in phase 2 is not common for small investors, if you want to learn more about the project do not hesitate to visit our webpage where you will find extended information.

Ability Pharma

real medicine for real life